Advertisement

One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI

      Highlights

      • Data comparing clinical outcomes among new-DESs in STEMI patients MVD who underwent primary PCI with culprit-only or multivessel PCI are limited.
      • BP-BES and DP-DES showed comparable safety and efficacy in STEMI patients with MVD who underwent two different reperfusion strategies.
      • In the total study population, the culprit-only PCI showed higher incidence of the total repeat revascularization than the multivessel PCI.

      Abstract

      Background and aims

      There are limited data comparing clinical outcomes among new-generation drug-eluting stents (DES) in ST-segment elevation myocardial infarction (STEMI) patients with multivessel coronary artery disease (MVD) who underwent primary percutaneous coronary intervention (PCI) with culprit-only or multivessel PCI. We investigated 1-year clinical outcomes between biodegradable-polymer (BP)-coated biolimus-eluting stent (BES) and durable-polymer (DP)-coated DES in STEMI patients with MVD who underwent two different reperfusion strategies.

      Methods

      A total of 4255 patients were enrolled and divided into two groups, a culprit-only (n = 2571, BP- [n = 264] or DP-DES [n = 2307]) or a multivessel PCI group (n = 1684, BP- [n = 145] or DP-DES [n = 1539]). The primary endpoint was major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), and total repeat revascularization. The secondary endpoint was the incidence of definite or probable stent thrombosis (ST).

      Results

      BP-BES and DP-DES showed a similar 1-year adjusted hazard ratio (HR) for MACE (culprit-only, adjusted hazard ratio [HR], 1.114; p = 0.740; multivessel, HR, 0.564; p = 0.167) and ST (culprit-only, HR, 1.110, p = 0.891; multivessel, HR, 0.375; p = 0.402). The adjusted HR for all-cause death, re-MI, and repeat revascularization were similar between the two groups. In the total population, the culprit-only PCI group showed a higher incidence of total repeat revascularization than the multivessel PCI group.

      Conclusions

      BP-BES and DP-DES showed comparable safety and efficacy in STEMI patients with MVD who underwent primary PCI with two different reperfusion strategies during a 1-year follow-up period.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dangas G.D.
        • Serruys P.W.
        • Kereiakes D.J.
        • et al.
        Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with De Novo native coronary artery lesions).
        JACC Cardiovasc. Interv. 2013; 6: 914-922
        • Hofma S.H.
        • Brouwer J.
        • Velders M.A.
        • et al.
        Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
        J. Am. Coll. Cardiol. 2012; 60: 381-387
        • Xu B.
        • Yang Y.
        • Yuan Z.
        • et al.
        RESOLUTE China RCT Investigators. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
        JACC Cardiovasc. Interv. 2013; 6: 664-670
        • Kang S.H.
        • Park K.W.
        • Kang D.Y.
        • et al.
        Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis.
        Eur. Heart J. 2014; 35: 1147-1158
        • Smits P.C.
        • Hofma S.
        • Togni M.
        • et al.
        Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
        Lancet. 2013; 381: 651-660
        • Kotani J.
        • Mintz G.S.
        • Castagna M.T.
        • et al.
        Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction.
        Circulation. 2003; 107: 2889-2893
        • Park D.W.
        • Clare R.M.
        • Schulte P.J.
        • et al.
        Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction.
        J. Am. Med. Assoc. 2014; 312: 2019-2027
        • O'Gara P.T.
        • Kushner F.G.
        • Ascheim D.D.
        • et al.
        ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2013; 127: e362-425
        • Thiele H.
        • Akin I.
        • Sandri M.
        • et al.
        CULPRIT-SHOCK investigators. One-year outcomes after PCI strategies in cardiogenic shock.
        N. Engl. J. Med. 2018; 379: 1699-1710
        • Jo H.S.
        • Park J.S.
        • Sohn J.W.
        • et al.
        Culprit-lesion-only versus multivessel revascularization using drug-eluting stents in patients with ST-segment elevation myocardial infarction: a Korean acute myocardial infarction registry-based analysis.
        Korean Circ J. 2011; 41: 718-725
        • Kim Y.H.
        • Her A.Y.
        • Jeong M.H.
        • et al.
        Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: comparison between STEMI and NSTEMI.
        Atherosclerosis. 2019; 280: 166-173
        • Bundhun P.K.
        • Wu Z.J.
        • Chen M.H.
        Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials.
        Medicine (Baltim.). 2016; 95: e2651
        • Raungaard B.
        • Jensen L.O.
        • Tilsted H.H.
        • et al.
        Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT). Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients underwent percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial.
        Lancet. 2015; 385: 1527-1535
        • Chevalier B.
        • Silber S.
        • Park S.J.
        • et al.
        NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
        Circ Cardiovasc Interv. 2009; 2: 188-195
        • Byrne R.A.
        • Kastrati A.
        • Kufner S.
        • et al.
        Intracoronary stenting and angiographic results: test efficacy of 3 Limus-eluting stents (ISAR-TEST-4) investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the intracoronary stenting and angiographic results: test efficacy of 3 Limus-eluting stents (ISAR-TEST-4) trial.
        Eur. Heart J. 2009; 30: 2441-2449
        • Stefanini G.G.
        • Byrne R.A.
        • Serruys P.W.
        • et al.
        Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients underwent percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
        Eur. Heart J. 2012; 33: 1214-1222
        • Lee H.J.
        • Park T.K.
        • Song Y.B.
        • et al.
        Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
        Int. J. Cardiol. 2015; 183: 190-197
        • von Birgelen C.
        • Sen H.
        • Lam M.K.
        • et al.
        Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (Dutch PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
        Lancet. 2014; 383: 413-423
        • Kolandaivelu K.
        • Swaminathan R.
        • Gibson W.J.
        • et al.
        Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.
        Circulation. 2011; 123: 1400-1409
        • Kubo T.
        • Akasaka T.
        • Kozuma K.
        • et al.
        NEXT Investigators. Vascular response to drug-eluting stent with biodegradable vs. durable polymer. Optical coherence tomography substudy of the NEXT.
        Circ. J. 2014; 78: 2408-2414
        • Ibanez B.
        • James S.
        • Agewall S.
        • ESC Scientific Document Group
        • et al.
        2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
        Eur. Heart J. 2017; 39: 119-177
        • Patel M.R.
        • Calhoon J.H.
        • Dehmer G.J.
        • et al.
        ACC/aats/aha/ase/asnc/scai/scct/sts 2016 appropriate use criteria for coronary revascularization in patients with acute coronary syndromes: a report of the American College of Cardiology appropriate use criteria task force, American association for thoracic surgery, American heart association, American society of echocardiography, American society of nuclear Cardiology, society for cardiovascular angiography and interventions, society of cardiovascular computed tomography, and the society of thoracic surgeons.
        J. Am. Coll. Cardiol. 2017; 69: 570-591
        • Pasceri V.
        • Patti G.
        • Pelliccia F.
        • et al.
        Complete revascularization during primary percutaneous coronary intervention reduces death and myocardial infarction in patients with multivessel disease: meta-analysis and meta-regression of randomized trials.
        JACC Cardiovasc. Interv. 2018; 11: 833-843
        • Wang C.H.
        • Zhang S.Y.
        • Jin X.F.
        Complete revascularization versus culprit-only revascularization in ST-segment elevation myocardial infarction and multivessel disease patients underwent primary percutaneous coronary intervention: a meta-analysis and trial sequential analysis.
        Int. J. Cardiol. 2017; 228: 844-852
        • Pimor A.
        • Auffret V.
        • Didier R.
        • et al.
        Immediate complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease treated by primary percutaneous coronary intervention: insights from the ORBI registry.
        Arch Cardiovasc Dis. 2018; 111: 656-665